Skip to main content

Table 3 Plasma miRNA results in MD patients vs. controls

From: Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach

miRNA plasma levelsa (/103)

MD

Controls

p value

N = 63

N = 26

-206

17.20 (4.29–63.96)

0.19 (0.12–0.64)

<0.0001

-144-5p

9.85 (0.00–169.32)

13.16 (6.53–19.63)

0.81

-146b

62.55 (0.00–176.97)

16.64 (6.86–33.02)

0.16

-15b

0.00 (0.00–19.61)

2.46 (0.81–3.93)

0.64

-195

9.01 (0.52–21.73)

13.63 (10.46–16.81)

0.053

-20b

61.74 (21.70–85.10)

35.95 (27.39–51.02)

0.048

-21

30.61 (0.00–110.97)

9.58 (5.86–18.33)

0.48

-221

0.00 (0.00–20.44)

10.61 (7.73–17.12)

0.001

-222

1923.17 (881.56–5111.93)

79.22 (43.34–169.52)

<0.0001

-26a

293.34 (121.00–554.69)

49.40 (26.58–63.10)

<0.0001

-29a

0.00 (0.00–0.00)

0.07 (0.00–1.11)

0.002

-29c

0.00 (0.00–1.43)

0.56 (0.27–2.72)

0.001

-342

2427.02 (1198.59–4185.82)

73.89 (45.30–171.19)

<0.0001

-378a-3p

30 (5.07–268.79)

0.00 (0.00–0.23)

<0.0001

-378a-5p

27.57 (8.84–81.04)

0.58 (0.30–1.79)

<0.0001

-451

184.13 (73.28–343.07)

144.45 (107.74–169.24)

0.19

-93

26.82 (0.00–66.29)

35.37 (25.60–49.70)

0.24

  1. (a) – Each miRNA plasma level was normalized to miR-16 plasma levels and thereafter multiplied by 103 in order to increase readability
  2. Bold text indicates a significant p-value of <0.05